Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 81.171
Filtrar
1.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-48434

RESUMO

A pasta não recomenda, neste momento, a vacinação dos adolescentes que não apresentem algum fator de risco. A orientação é baseada, entre outros fatores, em evidências científicas que consideram o baixo risco de óbitos ou casos mais graves da Covid-19 neste público


Assuntos
Vacinação/métodos , Saúde do Adolescente/normas , Comorbidade , Vacinas contra COVID-19
2.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-48425

RESUMO

Parecer da Associação de Obstetrícia e Ginecologia de São Paulo – SOGESP sobre a vacinação contra covid-19 para gestantes e puérperas que tomaram a primeira dose de vacina Astrazeneca/Oxford.


Assuntos
Vacinas contra COVID-19 , Vacinação , Período Pós-Parto , Gestantes
3.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-48418

RESUMO

O envio de vacinas para imunização de adolescentes, de 12 a 17 anos, deve começar no próximo dia 15 em todo o Brasil. Essa é a orientação do Ministério da Saúde, divulgada em uma Nota Técnica nesta quinta-feira (2)


Assuntos
Vacinação , Programas de Imunização , Adolescente
4.
Indian Pediatr ; 58(8): 709-717, 2021 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-34465657

RESUMO

OBJECTIVE: To estimate the disease and economic burden of pertussis amongst hospitalised infants in India. DESIGN: Multicentric hospital-based surveillance study. PARTICIPANTS: Hospitalised infants with clinical suspicion of pertussis based on predefined criteria. OUTCOME MEASURES: Proportion of infants with laboratory-confirmed pertussis, economic burden of pertussis amongst hospitalised infants. RESULTS: 693 clinically suspected infants were recruited of which 32 (4.62%) infants had laboratory-confirmed pertussis. Progressive cough with post-tussive emesis (50%) and pneumonia (34%) were the common clinical presentations; apnea in young infants was significantly associated with pertussis. Infants with pertussis were more likely to be younger (median age 102.5 days vs.157 days) and born preterm (42.9% vs 24.5%). Almost 30% infants with pertussis had not received vaccine for pertussis with 50% of these infants aged less than 2 months. Pertussis was associated with higher costs of hospitalisation, pharmacy and loss of working days by caregivers as compared to non-pertussis cases. CONCLUSIONS: Younger infants, those born preterm and those inadequately immunised against pertussis are at higher risk of pertussis infection. Timely childhood immunisation and introduction of maternal immunisation for pertussis can help in reducing the disease burden.


Assuntos
Coqueluche , Idoso de 80 Anos ou mais , Criança , Hospitalização , Hospitais , Humanos , Lactente , Recém-Nascido , Vacina contra Coqueluche , Atenção Terciária à Saúde , Vacinação , Coqueluche/diagnóstico , Coqueluche/epidemiologia , Coqueluche/prevenção & controle
5.
Pan Afr Med J ; 39: 93, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34466195

RESUMO

Widespread vaccination provides a means for countries to lift strict COVID-19 restrictions previously imposed to contain the spread of the disease. However, to date, Africa has secured enough COVID-19 vaccine doses for less than 5% of its population. With widespread vaccination not on the horizon for Africa, there is a strong emphasis on non-pharmaceutical interventions which include movement restrictions (lockdowns). This general COVID-19 pandemic response of imposing lockdowns, however, neglects to factor in non-fatal consequences leading to disruption socio-economic wellbeing of the society at large. The economy in most African countries can no longer sustain lockdown restrictions. Some studies have indicated that a hard lockdown statistical value of the extra lives saved would be dwarfed by its long-term cost. At the same time not responding to the threat of the pandemic will cost lives and disrupts the social fabric. This paper proffers ways to mitigate the both and advocate for better policymaking that addresses specific challenges in defined communities thus yield higher population welfare.


Assuntos
Vacinas contra COVID-19/provisão & distribuição , COVID-19/prevenção & controle , Tecnologia Digital , Política de Saúde , África , COVID-19/economia , Humanos , Formulação de Políticas , Quarentena/economia , Fatores Socioeconômicos , Vacinação/estatística & dados numéricos
6.
BMJ Case Rep ; 14(9)2021 Sep 03.
Artigo em Inglês | MEDLINE | ID: mdl-34479882

RESUMO

Localised herpes zoster infections spread by direct contact with active skin lesion, but airborne transmission is rare. We report a case of varicella from airborne transmission of a localised herpes zoster infection in a family. The patient was a 15-year-old boy who had never been vaccinated against the varicella-zoster virus (VZV). He likely developed varicella from his father, whom the patient lived with. The patient's father developed a localised herpes zoster infection 2 weeks prior. The patient's varicella was hypothesised to be due to VZV spread via airborne transmission from the father's localised infection. To decrease the number of varicella cases, routine vaccination of children against VZV is essential, and immunisation against VZV in middle-aged and elderly patients is also necessary.


Assuntos
Varicela , Herpes Zoster , Dermatopatias , Adolescente , Idoso , Criança , Herpesvirus Humano 3 , Humanos , Masculino , Pessoa de Meia-Idade , Vacinação
7.
Artigo em Russo | MEDLINE | ID: mdl-34486871

RESUMO

The serologic epidemiological analysis of intensity of anti-diphtheria and anti-tetanus post-vaccination population immunity in the Republic of Kyrgyzstan was carried out. The presence of immune defense was determined in 453 residents by detecting IgG to diphtheria and tetanus by enzyme-linked immunosorbent assay using test system RIDASCREEN Diphtherie IgG and RIDASCREEN Tetanus IgG (Germany, R-Biopharm). It was established that the level of antibodies depends on the age of individuals. The highest immune defense against diphtheria is present in adult population aged 20-29 years (100%) and 30 years and older (100%). The lowest level is detected in the group of children of 1-4 years old and is up to 30.6%. The proportion of individuals with protective titer of antibodies ≥ 0.10 for diphtheria was 88.5%. The population intensity of post-vaccination tetanus immunity high antibody titers were established in age groups of 15-19 years (92.9%), 20-29 years (93.3%) and 30 years and older (94.8%). There is relationship between level of antibody titers and the age. Thus, in children age group of 5-9 years, high level of protection was established, that amounted up to 60.4%, in adolescents of 10-14 years old this indicator was 40%, and the lowest level in children aged of 1-4 years old was 39.6%.


Assuntos
Difteria , Tétano , Adolescente , Adulto , Anticorpos Antibacterianos , Criança , Pré-Escolar , Difteria/epidemiologia , Difteria/prevenção & controle , Humanos , Lactente , Quirguistão/epidemiologia , Tétano/prevenção & controle , Vacinação , Adulto Jovem
8.
J R Soc Interface ; 18(182): 20210214, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34465208

RESUMO

The swift development of SARS-CoV-2 vaccines has been met with worldwide commendation. However, in the context of an ongoing pandemic there is an interplay between infection and vaccination. While infection can grow exponentially, vaccination rates are generally limited by supply and logistics. With the first SARS-CoV-2 vaccines receiving medical approval requiring two doses, there has been scrutiny on the spacing between doses; an elongated period between doses allows more of the population to receive a first vaccine dose in the short-term generating wide-spread partial immunity. Focusing on data from England, we investigated prioritization of a one dose or two dose vaccination schedule given a fixed number of vaccine doses and with respect to a measure of maximizing averted deaths. We optimized outcomes for two different estimates of population size and relative risk of mortality for at-risk groups within the Phase 1 vaccine priority order. Vaccines offering relatively high protection from the first dose favour strategies that prioritize giving more people one dose, although with increasing vaccine supply eventually those eligible and accepting vaccination will receive two doses. While optimal dose timing can substantially reduce the overall mortality risk, there needs to be careful consideration of the logistics of vaccine delivery.


Assuntos
COVID-19 , Vacinas , Vacinas contra COVID-19 , Humanos , SARS-CoV-2 , Vacinação
9.
Ugeskr Laeger ; 183(35)2021 08 30.
Artigo em Dinamarquês | MEDLINE | ID: mdl-34477089

RESUMO

The COVID-19-pandemic has had a huge impact on health and economics all over the world resulting in widespread vaccine development. Vaccine-induced immune thrombotic thrombocytropenia has been described, suggesting a link between the two adeno-vector vaccines ChAdOx1 nCoV-19 (Vaxzevria from AstraZeneca) and Ad26.COV2-S (Janssen from Johnson and Johnson). This rare clinical condition should be suspected in patients with headache, abdominal pain, suspected thrombosis or hemorrhage and thrombocytopenia within 3-30-day post vaccine. In this case report a previously healthy man had thrombocytopenia with fatal intracerebral haemorrhage which was suspected to be related to vaccine.


Assuntos
COVID-19 , Vacinas contra COVID-19 , Hemorragia Cerebral , Humanos , Masculino , SARS-CoV-2 , Vacinação
11.
MMW Fortschr Med ; 163(15): 29, 2021 09.
Artigo em Alemão | MEDLINE | ID: mdl-34478084
12.
Rev Chilena Infectol ; 38(3): 355-361, 2021 06.
Artigo em Espanhol | MEDLINE | ID: mdl-34479292

RESUMO

In March 2020, the World Health Organization (WHO) recommended that vaccination not be interrupted as long as countries could safely maintain this service in the context of the SARS-CoV-2 pandemic. WHO also warned about the risk of interruption of programmatic vaccination that generates an increase in the number of people susceptible to infections that are sought to be prevented with the use of vaccines and, therefore, an increase in the probability of disease outbreak. Along with increased morbidity and mortality in risk groups, vaccine-preventable disease outbreaks would put additional demand on the health system already burdened by COVID-19. In August 2020, WHO reported the interruption of essential health services in different countries as a result of the SARS-CoV-2 pandemic, which mainly affected routine and extramural vaccination. In Chile, routine vaccination coverage decreased during 2020 compared to the average coverage for the 2015-2019 period. The smallest decline was 0.39% for the hexavalent vaccine at 2 months of age and the largest decrease was 12.02% at 18 months for the same vaccine. The exception to the fall in coverage in 2020 was adult pneumococcal vaccination, which showed an increase of 0.8% compared to 2015-2019.


Assuntos
COVID-19 , SARS-CoV-2 , Adulto , Chile/epidemiologia , Humanos , Programas de Imunização , Pandemias/prevenção & controle , Vacinas Pneumocócicas , Vacinação
14.
Rev Chilena Infectol ; 38(3): 362-369, 2021 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-34479293

RESUMO

BACKGROUND: Since 2015, pertussis vaccine has been offered universally and free of charge to pregnant women in Uruguay. Although it is mandatory, vaccination coverage is not yet complete. AIM: To study the pertussis vaccination coverage in 2017 in pregnant women in two state hospitals and to search for barriere for uptaking the vaccine. METHODS: We conducted an observational, descriptive and transversal study, using a survey in patients undergoing immediate postpartum period. RESULTS: 884 surveys were analyzed (mean age 25.2 years; 16% teenagers, most of them in a relationship and incomplete high school). 317 women (36%) were vaccinated. Main barriere for uptaking Tdap vaccine were: teenage and being single were associated with a greater risk for the uptake. Not being aware of the vaccine mandatoriness and not being informed about its benefits were associated with 9,44 and 4 higher risks for not uptaking the vaccine (IC 95% 6.63-13.45 and IC 95% 2.43-6.41, respectively). Not believing in the benefits of pertussis vaccine during pregnancy was associated with 6.37 higher risk (OR 6.37; IC 95% 4.61-8.78). DISCUSSION: Most pregnant women in this study during 2017 did not uptake pertussis vaccine and did not have medical indication for it. The lack of information about the obligation and benefits, and also patients' beliefs about the vaccination were identified as barriere. Health professionals who treat pregnant women should recommend and inform about the benefits of pertussis vaccine for women and the infant, and create the necessary perception of risk, in order to improve the vaccination coverage.


Assuntos
Vacinas contra Difteria, Tétano e Coqueluche Acelular , Coqueluche , Adolescente , Adulto , Estudos Transversais , Feminino , Humanos , Lactente , Vacina contra Coqueluche , Gravidez , Gestantes , Uruguai , Vacinação , Coqueluche/prevenção & controle
15.
Clin Med (Lond) ; 21(5): e535-e538, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34507942

RESUMO

Longitudinal extensive transverse myelitis (LETM) is a rare but recognised complication of vaccination. We report the case of a 58-year-old man admitted to hospital 10 days after his first AstraZeneca COVID-19 vaccination with progressive neurological symptoms and signs, and investigations and imaging consistent with LETM.This case reviews the literature and the investigative process behind excluding other diagnoses given the patient's background of pulmonary sarcoidosis. It is unique in being the first UK report of a case of LETM with a strong temporal link to COVID-19 vaccination.


Assuntos
COVID-19 , Mielite Transversa , Vacinas contra COVID-19 , Humanos , Masculino , Pessoa de Meia-Idade , Mielite Transversa/induzido quimicamente , Mielite Transversa/tratamento farmacológico , SARS-CoV-2 , Vacinação/efeitos adversos
18.
Rev Bras Epidemiol ; 24: e210041, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34524364

RESUMO

OBJECTIVE: To investigate the relation between COVID-19 vaccine coverage and COVID-19-related mortality by age groups in Brazil in 2021. METHODS: Secondary data on COVID-19 deaths and vaccination coverage were retrieved to investigate COVID-19 mortality rate (MR) evolution as the vaccination against COVID-19 advanced in Brazil in 2021. Poisson regression with adjustment for age and Brazilian states was used to calculate the MR. RESULTS: By mid-April 2021, MR increased 2 - 3 times compared with the already high level in January for people aged 60 years or older, reaching the highest epidemic level of 5 - 15 per 100,000 inhabitants in this age group. Despite the following decline trend, by the end of May, the MR level was still about 50% and 80% higher for the age groups of 40 - 79 years and 80 years or older. The coverage concerning the first dose of COVID-19 vaccine reached 80% for people aged 60 - 69 years and exceeded 95% for those aged 70 years or older, but the second dose was only given to 26, 76 and 64% of the age groups of 60 - 69, 70 - 79, and 80 years or older, respectively. The age-standardized average MR over the study period was the highest in northern Brazilian states of Rondônia, Amazonas, Acre, and Roraima (range 6-8.4 per 100,000 inhabitants). CONCLUSIONS: COVID-19 vaccination coverage was below the level necessary to protect Brazilians from rising MR between January and May 2021. Urgent measures are necessary to increase the vaccine supply and the adherence to non-pharmacological protective measures.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Adulto , Idoso , Brasil/epidemiologia , Humanos , Pessoa de Meia-Idade , SARS-CoV-2 , Vacinação , Cobertura Vacinal
19.
J Int Med Res ; 49(9): 3000605211044378, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34528472

RESUMO

Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a patient with MS treated with ocrelizumab. The intervals between ocrelizumab infusions and vaccination were as recommended by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. A reactive immune response was observed in this patient following vaccination. This suggests that appropriate intervals between ocrelizumab infusions and COVID-19 vaccinations may permit the generation of efficacious immune responses in patients receiving B-lymphocyte depleting therapies.


Assuntos
COVID-19 , Esclerose Múltipla , Anticorpos Monoclonais Humanizados , Formação de Anticorpos , Humanos , Esclerose Múltipla/tratamento farmacológico , SARS-CoV-2 , Vacinação
20.
MMWR Morb Mortal Wkly Rep ; 70(37): 1284-1290, 2021 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-34529637

RESUMO

COVID-19 vaccine breakthrough infection surveillance helps monitor trends in disease incidence and severe outcomes in fully vaccinated persons, including the impact of the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19. Reported COVID-19 cases, hospitalizations, and deaths occurring among persons aged ≥18 years during April 4-July 17, 2021, were analyzed by vaccination status across 13 U.S. jurisdictions that routinely linked case surveillance and immunization registry data. Averaged weekly, age-standardized incidence rate ratios (IRRs) for cases among persons who were not fully vaccinated compared with those among fully vaccinated persons decreased from 11.1 (95% confidence interval [CI] = 7.8-15.8) to 4.6 (95% CI = 2.5-8.5) between two periods when prevalence of the Delta variant was lower (<50% of sequenced isolates; April 4-June 19) and higher (≥50%; June 20-July 17), and IRRs for hospitalizations and deaths decreased between the same two periods, from 13.3 (95% CI = 11.3-15.6) to 10.4 (95% CI = 8.1-13.3) and from 16.6 (95% CI = 13.5-20.4) to 11.3 (95% CI = 9.1-13.9). Findings were consistent with a potential decline in vaccine protection against confirmed SARS-CoV-2 infection and continued strong protection against COVID-19-associated hospitalization and death. Getting vaccinated protects against severe illness from COVID-19, including the Delta variant, and monitoring COVID-19 incidence by vaccination status might provide early signals of changes in vaccine-related protection that can be confirmed through well-controlled vaccine effectiveness (VE) studies.


Assuntos
Vacinas contra COVID-19/administração & dosagem , COVID-19/epidemiologia , COVID-19/prevenção & controle , Hospitalização/estatística & dados numéricos , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Idoso , COVID-19/mortalidade , COVID-19/terapia , Humanos , Incidência , Pessoa de Meia-Idade , Estados Unidos/epidemiologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...